WuXi AppTec shares firm some a week after tepid Hong Kong IPO debut

Facade of HKSE
WuXi AppTec shares firm some a week after the company debuted its IPO on the Hong Kong exchange amid a tepid investor response. (iStock)

WuXi AppTec saw its shares firm some a week after the company debuted its IPO on the Hong Kong exchange amid a tepid investor response that saw the stock see little movement.

Shares of the Chinese producer of biologics, antibodies, biological diagnostics and other products closed at HK$67.5 Wednesday compared to its public debut price close of HK$68 Dec. 12. The shares were offered at HK$68.

The company was among a number of subdued IPOs in Hong Kong this year due to unease among investors amid trade tensions between China and the U.S., Reuters previously reported.

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

WuXi AppTec raised $1 billion (U.S.) in the public offering that company offices have said will be used to boost its global capability and capacity, including the possible acquisitions of CROs and CDMO/CMOs. The company also said it plans to develop new technologies with the money in addition to repaying some bank loans.

“We aspire to foster a networked healthcare ecosystem, where scientists and entrepreneurs are empowered to participate, and together, realize our vision—every drug can be made and every disease can be treated,” Ge Li, Ph.D., WuXi AppTec’s chairman and chief executive, said in an IPO launch statement.

With last week’s listing, WuXi AppTec completed its public offering plans for both A-shares and H-shares.

Earlier this month, WuXi AppTec announced the expansion of its San Diego facility designed to establish a center of excellence in screening, discovery biology, pharmacology, and small molecule process R&D that includes phase 1 GMP manufacturing. 

Editor's Note: This story has been updated with WuXi's correct Wednesday close price in Hong Kong.

Read more on

Suggested Articles

Gottlieb challenged industry and academia to invest in new approaches and realign incentives to make clinical research more agile and effective.

Chinese biotech HitGen has inked a collaboration deal with India’s Sun Pharma Advanced Research arm to identify novel small molecule leads.

Charles River Labs has inked a licensing deal with drug discovery and development services provider Crown Bioscience for expanded access to the ZDSD rat model.